China BCT Pharmacy Group, Inc. (CNBI)

Other OTC - Other OTC Delayed Price. Currency in USD

0.0001

0.0000

(0.00%)

As of 10:00AM EST. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.0001
Open	0.0001
Bid	0.0000 x 0
Ask	0.0000 x 0
Day's Range	0.0001 - 0.0001
52 Week Range	0.0001 - 0.0001
Volume	60
Avg. Volume	0

Market Cap	343,389
Beta (5Y Monthly)	-1.80
PE Ratio (TTM)	∞
EPS (TTM)	0.0000
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CNBI

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

CHINA BCT PHARMACY GROUP INC
Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Rating
Fair Value
Economic Moat
3 days agoMorningstar